Full Text View
Tabular View
No Study Results Posted
Related Studies
Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects
This study has been completed.
Study NCT00699777   Information provided by Procter and Gamble
First Received: June 16, 2008   Last Updated: December 15, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Osteoporosis
More general conditions related to this trial
Bone Diseases
Bone Diseases, Metabolic
Musculoskeletal Diseases
Interventions listed in this trial
Risedronate
Additional drug interventions recognized in this trial
Etidronic Acid
Risedronic acid
More general drug interventions related to this trial
Bone Density Conservation Agents
Calcium Channel Blockers
Cardiovascular Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Procter and Gamble
Sanofi-Aventis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services